Cobra Biologics Expands GMP Production Capacity
Cobra Biologics installs a new single-use bioreactor to expand its antibody GMP production capacity.
Cobra Biologics reported the installation of a 1000L HyClone single-use bioreactor (SUB) at the company’s center of excellence for mammalian antibody and recombinant protein production. This is the most recent development in the company's on-going expansion plans. The installation of the SUB technology is in response to an increased demand for contract manufacturing services and the drive to be a supplier of commercial antibodies and recombinant proteins.
Cobra’s expansion began with the acquisition of a purpose built aseptic manufacturing facility in 2011, providing fill and finish services for pre-filled syringes, vials, and freeze drying /lyophilization for biologics and pharmaceuticals.
Source: Cobra Biologics
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
